![Calliditas Therapeutics AB](/common/images/company/N_CALT.png)
Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients ... Calliditas Therapeutics AB is a biopharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys. Show more
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, July 26, 2024 STOCKHOLM, July 26, 2024...
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM, July 26, 2024 STOCKHOLM, July 26, 2024...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM, July 26, 2024 STOCKHOLM, July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM, July 26, 2024 STOCKHOLM, July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM, July 4, 2024 STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ STOCKHOLM:...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM, July 4, 2024 STOCKHOLM, July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM, June 18, 2024 STOCKHOLM, June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM, June 18, 2024 STOCKHOLM, June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX...
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) PR Newswire STOCKHOLM, June 17, 2024 STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.